John E Anderson, MD, discusses why primary care lags in CGM adoption despite proven benefits, stressing that it's largely a lack of familiarity and that's easily overcome.

FMX 2025: A family medicine clinician discusses the clinical significance of acute, subacute, and chronic cough timeframes and their differential diagnoses.

Psoriasis, lichen planus, and pityriasis rosea share overlapping presentations and comorbidities, but distinct pathophysiologies require accurate diagnosis and tailored therapeutic approaches.

Sarah C. Nosal, MD, FAAFP, takes the helm as AAFP President, emphasizing community-focused family medicine and innovative healthcare solutions.

The approval of roflumilast 0.05% provides a steroid-free, once-daily treatment option for safe and effective long-term management of pediatric eczema.

Barriers to increasing guideline-recommended CRC screening rates are slow to fall, but continued and focused counseling and advocacy in primary care will support the progress.

Experts discuss the importance of in-lab sleep studies for patients with significant comorbidities or complex sleep disorders such as parasomnias, emphasizing the comprehensive monitoring and technician oversight they provide, as well as their role in confirming or clarifying home test results; they also highlight that clear patient instructions and maintaining usual routines are vital to ensuring accurate and reliable sleep study outcomes.

Experts discuss the evolving role of home-based sleep testing in diagnosing obstructive sleep apnea (OSA), noting its growing popularity due to convenience and patient comfort, while emphasizing that device simplicity, patient education, and pretest probability are key to reliability—though in-lab polysomnography remains essential for complex or comorbid cases, underscoring the complementary value of both approaches in modern sleep medicine.

Get a first look at can’t-miss sessions from day 2 of FMX 2025—from vaccines and metabolic health to dementia, women’s care, and AI in family medicine.

Semaglutide and tirzepatide "should be first-line treatment" for people with obesity and its myriad of complications, says EU obesity professional association.

From vaccines to reproductive health to AI, here are 16 sessions you won't want to miss at FMX 2025.

The ReCODE program targets metabolic, infectious, immune, vascular, and toxic exposures, elements that underlie both mood and cognition, study authors said.

FDA did not announce the September 30 approval, which took place despite strong partisan opposition and during an uncompleted review of the drug's safety.

Moore describes the ACIP's shared decision making approach to COVID-19 vaccination as a "passive recommendation" that will surely exclude at-risk US populations.

Today's episode highlights arrhythmias as CVD risk markers, influenza vaccine safety, salt substitute use, preconception CT scan risks, and global diabetes care gaps.

The premonitory constellation of neurologic, autonomic, and behavioral symptoms is increasingly understood as the earliest manifestation of migraine pathophysiology.

Evolocumab significantly reduced major cardiovascular events in high-risk patients without prior heart attack or stroke, making it the first PCSK9 inhibitor with proven benefit in both primary and secondary prevention.

Preview the top sessions at the AAFP Family Medicine Experience (FMX) 2025. From vaccines and obesity care to dementia and LGBTQ+ health, here are 10 highlights for family physicians.

Linus Health will demonstrate advances in remote assessment platforms and digital biomarkers of cognitive health that can bring precision medicine to primary care.

Remibrutinib is the first oral BTK inhibitor for chronic spontaneous urticaria, with a dual mechanism of action that blocks 2 key autoimmune mechanisms.

This year, the FMX Main Stage presenters will be led by Vivek H Murthy, the 21st US Surgeon General. Learn more about him and the 2 other inspiring guests.

The FDA has granted fast track designation to BMS-986446, an anti–microtubule binding region tau antibody in phase 2 trials for early Alzheimer disease.

Lipocene expects to announce interim safety data from the study this quarter and said the phase 3 program results will support the company's NDA in 2026.

The binational cohort study of exposure to 4 traditional CVD risk factors over time revealed that 99% of CVD events were preceded by suboptimal levels of at least one.